BDBM517007 N-(3-fluoro-4-((3-((2- hydroxy-2- methylpropyl)amino)- 1H-pyrazolo[3,4- b]pyridin-4- yl)oxy)phenyl)-3-(4- fluorophenyl)-1- isopropyl-2,4-idoxo- 1,2,3,4- tetrahydropyrimidine-5- carboxamide::US11104676, Example 77

SMILES CC(C)n1cc(C(=O)Nc2ccc(Oc3ccnc4[nH]nc(NCC(C)(C)O)c34)c(F)c2)c(=O)n(-c2ccc(F)cc2)c1=O

InChI Key InChIKey=XEPIWGLSVOVBHX-UHFFFAOYSA-N

Data  11 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 11 hits for monomerid = 517007   

TargetTyrosine-protein kinase receptor UFO(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM517007(N-(3-fluoro-4-((3-((2- hydroxy-2- methylpropyl)ami...)
Affinity DataIC50:  700nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase Mer(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM517007(N-(3-fluoro-4-((3-((2- hydroxy-2- methylpropyl)ami...)
Affinity DataIC50:  2.80E+3nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase receptor TYRO3(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM517007(N-(3-fluoro-4-((3-((2- hydroxy-2- methylpropyl)ami...)
Affinity DataIC50:  7.20E+3nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHepatocyte growth factor receptor(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM517007(N-(3-fluoro-4-((3-((2- hydroxy-2- methylpropyl)ami...)
Affinity DataIC50:  2.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM517007(N-(3-fluoro-4-((3-((2- hydroxy-2- methylpropyl)ami...)
Affinity DataIC50:  4.80nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHepatocyte growth factor receptor [Y1230H](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM517007(N-(3-fluoro-4-((3-((2- hydroxy-2- methylpropyl)ami...)
Affinity DataIC50:  5.80nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHepatocyte growth factor receptor [D1228N](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM517007(N-(3-fluoro-4-((3-((2- hydroxy-2- methylpropyl)ami...)
Affinity DataIC50:  4.30nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHepatocyte growth factor receptor [F1200I](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM517007(N-(3-fluoro-4-((3-((2- hydroxy-2- methylpropyl)ami...)
Affinity DataIC50:  2.20nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHepatocyte growth factor receptor [L1195V](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM517007(N-(3-fluoro-4-((3-((2- hydroxy-2- methylpropyl)ami...)
Affinity DataIC50:  36nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHepatocyte growth factor receptor [Y1230C](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM517007(N-(3-fluoro-4-((3-((2- hydroxy-2- methylpropyl)ami...)
Affinity DataIC50:  1.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHepatocyte growth factor receptor [D1228H](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM517007(N-(3-fluoro-4-((3-((2- hydroxy-2- methylpropyl)ami...)
Affinity DataIC50:  4.10nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent